Early introduction of biologic therapy improves Crohn's disease outcomes
A large-scale study of medical claims data shows that introducing sophisticated biologic therapies early in the course of treatment for Crohn's disease improves response to medication and reduces the need for surgery.
There is no known cure for Crohn's disease, and traditional treatment is focused on a "step-up" strategy of managing inflammatory symptoms, starting with simpler and less costly oral medications such as aminosalicylates (5-ASAs) and corticosteroids, and escalating through a series of steps to more expensive biological therapies that target specific proteins in the immune system's inflammatory response.
David Rubin, MD, associate professor of medicine and co-director of the University of Chicago Medicine's Inflammatory Bowel Disease Center, studied a newer "top-down" strategy that reverses this order of treatment. He found that patients treated with biologic therapies earlier were significantly less likely to need steroids, lose response to their biologic therapy, and require surgery related to their Crohn's disease. "We're essentially reversing the management strategy in Crohn's disease," Rubin said.
He emphasized that the medications often used first for patients with Crohn's are also the least effective and carry risks for side effects. "We've long discussed and debated that 5-ASAs don't work in the majority of Crohn's patients, and certainly don't change any outcomes," he said. "Steroids are ineffective long-term and are also dangerous because they have significant side effects such as infections."
Crohn's is a disorder in which the body's immune system appears to have lost the ability to regulate itself and becomes overactive, causing progressive damage to the bowel structure and function. Patients often need bowel surgery to repair this damage. Researchers have made great progress finding genetic and environmental contributors to Crohn's disease, but the actual cause is unknown.
Rubin said that physicians have questioned the effectiveness of the step-up strategy because patients experience little relief while being treated with medications before they receive the biological therapies. During that time, they suffer from active disease, have low rates of remission and often appear to lose response to the biological therapies.
In recent years a treatment strategy that starts with the targeted biologic therapy as a first option has been explored in controlled clinical trials. The encouraging results suggested that such an approach results in higher remission rates. However, it was not clear whether this top-down approach would translate to the general population of patients with Crohn's disease, or whether such an approach would maintain the response to biologic therapy and decrease the need for surgery.
The Food and Drug Administration approved the first targeted biologic therapy for Crohn's disease in 1998 and the second two in 2007 and 2008. Rubin said physicians are hesitant to prescribe them earlier because they are expensive, must be administered through injections instead of pills and are typically saved until last,. "Patients and doctors are nervous about immune suppressive therapies. The perception in the current treatment algorithm is that the therapies saved for last must also be the most dangerous," he said. "But that's the wrong thinking, and by delaying their prescription it may be a self-fulfilling prophecy because by then patients have suffered more damage to their bowels and are less likely to respond favorably."
In the study, published in the journal Inflammatory Bowel Diseases, Rubin and his colleagues analyzed health insurance claims from a database that includes records from more than 94 commercial health plans throughout the United States. Patients eligible for the study had to be enrolled in the same health plan continuously for at least six months before the first claim related to Crohn's and stay enrolled for at least 12 months after the first claim for anti-TNF treatments.
Rubin then separated these patients into three groups: those who followed the traditional step-up therapy starting with 5-ASAs or corticosteroids before anti-TNF treatment, those who had immunosuppressive therapy (but not 5-ASAs) before anti-TNF treatment, and those who started anti-TNF treatment within 30 days of their first prescription for Crohn's disease.
In general, the group that started anti-TNF treatment early had significantly lower rates of continuous steroid use to treat flare-ups than the other groups, lower rates of escalation of dosage for their medications and needed fewer surgeries related to Crohn's disease. "This is the first time we did a large assessment of the top-down, early-TNF strategy using claims databases," Rubin said. "It gave us lots of detail and lots of information, much larger than with a controlled trial. We could look at hundreds of thousands of patients in order to get a big picture of how effective these approaches are in treating Crohn's. It's also the first time we were able to examine surgical outcomes associated with this strategy."
"Having a new class of therapies and having a culture change in GI takes a lot of discussions," he said. "This paper contributes to the discussion about how important this kind of treatment is because it changes the outcomes for people suffering from Crohn's disease."
Provided by University of Chicago Medical Center
- ECP may be effective in treating Crohn's disease May 25, 2007 | not rated yet | 0
- Clinical trial seeks to improve patient treatment for Crohn's disease Jan 04, 2010 | not rated yet | 0
- Clinical trial success for Crohn's disease cell therapy Mar 31, 2011 | not rated yet | 0
- Omega-3's no help for Crohn's sufferers Apr 08, 2008 | not rated yet | 0
- 2-drug combo twice as effective for Crohn's disease remission Apr 14, 2010 | not rated yet | 0
- Motion perception revisited: High Phi effect challenges established motion perception assumptions Apr 23, 2013 | 3 / 5 (2) | 2
- Anything you can do I can do better: Neuromolecular foundations of the superiority illusion (Update) Apr 02, 2013 | 4.5 / 5 (11) | 5
- The visual system as economist: Neural resource allocation in visual adaptation Mar 30, 2013 | 5 / 5 (2) | 9
- Separate lives: Neuronal and organismal lifespans decoupled Mar 27, 2013 | 4.9 / 5 (8) | 0
- Sizing things up: The evolutionary neurobiology of scale invariance Feb 28, 2013 | 4.8 / 5 (10) | 14
Differences of Classical Mechanics when learned with Calc vs algebra?
3 hours ago what are the differences? Every example I find usually has a derivative or integral or some kind of calculus defined concept that seems to make it...
what is the distance traveled
7 hours ago Hi. I have newly started to study mechanical physics. based on study, I conduct a simple experiment. But unfortunately i am unable apply the laws in...
Image of a Convex Lens Cut in Half Horizontally
11 hours ago Hello everyone, A friend of mine came up with this question in class and I really do not have a good answer. Suppose you have a convex lens...
Ray tracing throught optical system of thick lenses
11 hours ago Can you advise me a free software that allow to draw rays passed throught system of thick lenses (preferable in 3D)?
Faraday's law on circular wire
12 hours ago In my examples on Faraday's law in my book, they use a drawing of a magnet approaching a circular wire. The changing magnetic flux then induces an...
Specific Exergy vs Specific Flow Exergy
13 hours ago I'm having some difficulty understanding exactly what the difference between the definitions of these values are. As I understand it, in terms of...
- More from Physics Forums - Classical Physics
More news stories
The negative effects of poorly controlled asthma symptoms on sleep quality and academic performance in urban schoolchildren has been confirmed in a new study.
Inflammatory disorders May 21, 2013 | not rated yet | 0
Patients with inflammatory bowel disease (IBD) are at higher risk of melanoma, a form of skin cancer, report researchers at Mayo Clinic. Researchers found that IBD is associated with a 37 percent greater risk for the disease. ...
Inflammatory disorders May 20, 2013 | 4.5 / 5 (2) | 0
(Medical Xpress)—Inflammation is an important response in the body - it helps you to kill off invaders such bacteria that could cause a harmful infection. But if it's chronic or uncontrolled, inflammation can also cause ...
Inflammatory disorders May 14, 2013 | 5 / 5 (1) | 0 |
New research by medical students working in the Breathe Well Centre of Research Excellence at the UTAS School of Medicine has revealed swimming has health benefits for young people with asthma, with no adverse effects on ...
Inflammatory disorders May 10, 2013 | 5 / 5 (1) | 0
An estimated 4,837,000 asthmatics with allergic bronchopulmonary aspergillosis (ABPA) could benefit substantially from antifungal treatment, say researchers from The University of Manchester and the University of Toronto.
Inflammatory disorders May 08, 2013 | not rated yet | 0
Calorie information in fast food restaurants used by 40 percent of 9-18 year olds when making food choices
A new study published online today (Thursday) in the Journal of Public Health has found that of young people who visited fast food or chain restaurants in the U.S. in 2010, girls and youth who were obese were more likely ...
59 minutes ago | not rated yet | 0
(HealthDay)—Migraines and depression can each cause a great deal of suffering, but new research indicates the combination of the two may be linked to something else entirely—a smaller brain.
3 hours ago | 5 / 5 (1) | 0 |
Swiss scientists reveal the mechanism responsible for aging hidden deep within mitochondria—and dramatically slow it down in worms by administering antibiotics to the young.
7 hours ago | 4.5 / 5 (2) | 0 |
Until now, little was scientifically known about the human potential to cultivate compassion—the emotional state of caring for people who are suffering in a way that motivates altruistic behavior.
4 hours ago | 5 / 5 (1) | 2 |
Researchers from Queen Mary, University of London have led the largest sequencing study of human disease to date, investigating the genetic basis of six autoimmune diseases.
7 hours ago | not rated yet | 0 |
A new approach for immunizing against influenza elicited a more potent immune response and broader protection than the currently licensed seasonal influenza vaccines when tested in mice and ferrets. The vaccine ...
4 hours ago | not rated yet | 0 |